NCI contracts Louisville company to advance early cancer diagnos - WDRB 41 Louisville News

NCI contracts Louisville company to advance early cancer diagnosis

Posted: Updated:

LOUISVILLE, Ky (WDRB) -- A Louisville company has received a contract to help further the science of early cancer diagnosis.

PGXL Technologies is one of only four companies awarded the contract. WDRB got a rare glimpse inside the labs where it all happens.

The $300,000 contract from the National Cancer Institute was awarded to PGXL Technologies in the quest to detect circulating tumor cells.

"A circulating tumor cell is a cell that has been shed from a primary tumor so those cells are really dangerous to the cancer patient," said Dr. Lori Millner, Chemical Chemistry Fellow at U of L Hospital.

That's where a high tech piece of equipment comes in.

"It allows us to get down to the single cell level which has been a major challenge in the field of cancer," said Dr. Kevin Goudy, PGXL Director of Research and Development.

"The big keyword in healthcare right now is individualize medicine, personalize medicine. That's what this machine is allowing us to do. Give the right medicine to the right patient at the right time," Millner told WDRB.

It's called DEPArray technology and it's the most advanced single cell isolation technology in the world.

"That machine can detect those very rare cells that are so dangerous to the cancer patient," she said.

Doctors call it cutting edge and say it will revolutionize cancer detection and treatment in the future.

"We're actually able to look at a single cell and view it and see what the outside of the cell looks like and the inside of the cell and it's genetic material," Millner added.

That's beneficial because they say all cancer is different.

"A medicine that would work for one patient is not the same, even though it's the same type of cancer, it's not the same medication that's going to work for another patient," Millner said.

"It really allows us to focus in and focus on you and what's best for you," said Goudy.

"Being able to really investigate those cells specifically will help us prevent metastatic cancer from occurring which is the ultimate goal," said Millner.

If you'd like to learn more about the research that happens at PGXL, click here.

Copyright 2013 by WDRB News. All rights reserved.

Powered by Frankly
All content © Copyright 2000 - 2017 WDRB. All Rights Reserved. For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices.